R&B singer Nivea’s recent leukemia diagnosis is opening a larger conversation about how blood cancer affects Black women, even though the disease is diagnosed less frequently in Black women than in several other groups.
The 44-year-old “Don’t Mess With My Man” singer revealed during a July 21 appearance on “Cadillac Chronicles” that she was diagnosed earlier this year and has been receiving treatment.
“Well, first of all, I was diagnosed with leukemia earlier this year, and I’m so grateful to God,” Nivea shared. “I’ve been going through treatment, and everything is going great so far. And I expect it to continue. Amen, amen, amen.”
Nivea has not revealed which type of leukemia she has. That detail matters because leukemia is not one single disease. It is a broad category of cancers affecting the blood and blood-forming tissues, including bone marrow. Some forms develop quickly, while others progress more slowly. Treatment and survival can vary widely depending on the specific type, a patient’s age, genetics and overall health.
According to the National Cancer Institute’s Surveillance, Epidemiology and End Results program, the overall leukemia incidence rate among non-Hispanic Black women was 9.7 cases per 100,000 women annually from 2019 through 2023.
That compares with 12.5 cases per 100,000 non-Hispanic White women and 11.5 cases per 100,000 women across all racial and ethnic groups.
The leukemia death rate among non-Hispanic Black women was 4.0 per 100,000 from 2020 through 2024. The rate was 4.6 among non-Hispanic White women and 4.3 among women overall.
Those figures mean Black women are not diagnosed with or dying from leukemia at the highest rates nationally. However, lower population rates do not mean Black women face fewer obstacles once the disease enters their lives.
Leukemia outcomes are shaped by far more than the cancer itself. Access to experienced specialists, health insurance, transportation, paid leave, timely testing, treatment centers and clinical trials can all influence how quickly a patient receives care and which options become available.
The American Cancer Society reported that Black women have a 10 percent higher overall cancer mortality rate than White women despite having a 9 percent lower overall cancer incidence rate. Researchers largely connect that wider cancer gap to unequal social and economic conditions, access to quality care and structural racism across the health care system.
The broad leukemia numbers do not tell the entire story because each subtype behaves differently.
Researchers have paid particular attention to racial disparities involving acute myeloid leukemia, commonly called AML. The fast-growing blood cancer is one of the most common forms of acute leukemia in adults.
Studies have found that Black patients with AML may experience worse survival and can be less likely to receive intensive chemotherapy or a potentially lifesaving stem cell transplant. Researchers have also examined how neighborhood conditions, income, treatment access and structural racism contribute to the gap.
Not every study reaches the exact same conclusion. A large 2024 analysis found better adjusted survival among Black and Asian AML patients than White patients in its study population, demonstrating why researchers warn against treating race as a biological explanation by itself. The patient group, type of leukemia, age, genetic mutations and treatment received can significantly change the results.
In other words, the issue is not as simple as saying leukemia is automatically more deadly for every Black woman. The more accurate concern is whether Black patients receive an early diagnosis, complete testing, specialized treatment and access to the same medical advances as other patients.
Leukemia can interfere with the production of normal white blood cells, red blood cells and platelets. Depending on the type, symptoms may include persistent fatigue, repeated infections, unexplained fever, easy bruising, unusual bleeding, weight loss, night sweats, swollen lymph nodes or bone pain.
Many of those symptoms can resemble far more common health problems. Fatigue may be blamed on work, motherhood, stress or lack of sleep. Heavy bleeding may be dismissed as a menstrual issue. Frequent illness may not immediately appear connected to cancer.
There is no standard population-wide screening test for leukemia like there is for certain breast, cervical or colorectal cancers. The disease is often discovered after symptoms lead to a complete blood count, additional laboratory testing or a bone marrow examination.
That makes listening to the body and receiving timely medical attention especially important when symptoms are persistent, unexplained or getting worse.
Nivea said her diagnosis changed her outlook and pushed her to approach life with intention.
Her personal prognosis cannot be determined from general leukemia statistics, particularly because she has not shared her subtype or treatment plan. Still, her announcement places a familiar Black woman’s face on an illness that is often discussed only through charts and percentages.
For Black women, the takeaway is not panic. It is awareness, advocacy and making sure serious symptoms are not ignored or dismissed. Nivea’s revelation is personal, but the conversation it sparked is much bigger than one celebrity diagnosis.
